Jin Pengfei
Master's Supervisor
Research Interests: Geriatric Pharmacy, Drug Safety Evaluation
Tel: +86-010-85133620
Email: j790101@163.com
EDUCATION
Doctor of Philosophy, Shenyang Pharmaceutical University (2005)
Bachelor of Science, Shenyang Pharmaceutical University (2001)
PROFESSIONAL EXPERIENCE
2005 - present Beijing Hospital, National Center of Gerontology
Junior Pharmacist, Department of Pharmacy (2005-2006)
Pharmacist-in-Charge, Department of Pharmacy (2006-2010)
Associate Chief Pharmacist, Department of Pharmacy (2010-2015)
Chief Pharmacist, Department of Pharmacy (2015-present)
Director for Department of Pharmacy (2021-present)
ACADEMIC APPOINTMENTS
12th National Pharmacopoeia Commission, Member
Geriatric Pharmacy Specialty Committee, China Medical Education Association, Chairman
8th Academic Committee, Beijing Hospital, National Center of Gerontology, Member
7th Ethics Committee, Beijing Hospital, National Center of Gerontology, Member
2nd Editorial Board, Aging Medicine, Member
REPRESENTATIVE PUBLICATIONS
1. Yuanchao Zhu, Fei Zhao, Yubing Zhu, Xingang Li, Deshi Dong, Bolin Zhu, Jianchun Li, Xin Hu, Zinan Zhao, Wenfeng Xu, Yang Jv, Dandan Wang, Yingming Zheng, Yiwen Dong, Lu Li, Shilei Yang, Zhiyuan Teng, Ling Lu, Jingwei Zhu, Linzhe Du, Yunxin Liu, Lechuan Jia, Qiujv Zhang, Hui Ma, Ana Zhao, Hongliu Jiang, Xin Xu, Jinli Wang, Xuping Qian, Wei Zhang, Tingting Zheng, Chunxia Yang, Xuguang Chen, Kun Liu, Huanhuan Jiang, Dongxiang Qu, Jia Song, Hua Cheng, Wenfang Sun, Hanqiu Zhan, Xiao Li, Yafeng Wang, Aixia Wang, Li Liu, Lihua Yang, Nan Zhang, Shumin Chen, Jingjing Ma, Wei Liu, Xiaoxiang Du, Meiqin Zheng, Liyan Wan, Guangqing Du, Hangmei Liu, Pengfei Jin*. Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study. Acta Pharmaceutica Sinica B, 2025, 15(1):123-132. (SCIE, Q1, IF-2024=14.6)
2. Zinan Zhao, Mengyuan Fu, Can Li, Zhiwen Gong, Ting Li, Kexin Ling, Huangqianyu Li, Jianchun Li, Weihang Cao, Dongzhe Hong, Xin Hu, Luwen Shi, Xiaodong Guan, Pengfei Jin*. Prescribing rate, healthcare utilization, and expenditure of older adults using potentially inappropriate medications in China: A nationwide cross-sectional study, Chinese Medical Journal, 2025, 138(23):3163-3167. (SCIE, Q1, IF-2024=7.3)
3. Tian Zhang, Ting Li, Pengfei Jin*. Proton pump inhibitor use and cardiovascular risk, all-cause, and cardiovascular mortality across baseline eGFR categories: a longitudinal study. Renal Failure, 2025, 47: 2594258. (SCIE, Q1, IF-2024=3)
4. Yuanchao Zhu, Bolin Zhu, Pengfei Jin*. Medication Administration Through Feeding Tubes in a Tertiary Hospital: A Retrospective Observational Study. Risk Management and Healthcare Policy, 2025, 18: 319–328. (SCIE, Q3, IF-2024=2)
5. Tian Zhang, Ting Li, Pengfei Jin*. Global, regional, and national burden of cardiovascular disease attributable to kidney dysfunction (1990–2021) with projections to 2050: analysis of the 2021 Global Burden of Disease study. Renal Failure, 2025, 47:2472039. (SCIE, Q1, IF-2024=3)
6. Ting Li, Miaomiao Zhang, Tian Zhang, Shaoqiang Li, Chen Kou, Ming Zhao, Jing Huang, Weihang Cao, Pengfei Jin*. Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database. International Journal of Cancer, 2024: 1-15. (SCIE, Q1, IF-2024=4.7)
7. Pengfei Jin, Xiong Lin, Wenfeng Xu, Kangning Li, Xiaoxiao Zhao, Sirui Guo, Zinan Zhao, Lujie Jiang, Feng Liao, Longgang Chang, Min Wang, Yanmin Liu, Shaolei Huang, Zhangran Chen*, Fusui Ji*. The feasibility of using pathobiome strains as live biotherapeutic products for human use. iMeta, 2024, 3: e202. (SCIE, Q1, IF-2024=33.2)
8. Jianchun Li, Weihang Cao, Fei Zhao, Pengfei Jin*. Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective, BMC Public Health, 2024, 2024(24): 436. (SCIE, Q1, IF-2024=3.6)